ZA200500021B - 1-(Aminoalkyl)-3-sylfonnylindole and -indazole derivatives as 5-hydroxytryptamine-5 ligands - Google Patents
1-(Aminoalkyl)-3-sylfonnylindole and -indazole derivatives as 5-hydroxytryptamine-5 ligands Download PDFInfo
- Publication number
- ZA200500021B ZA200500021B ZA200500021A ZA200500021A ZA200500021B ZA 200500021 B ZA200500021 B ZA 200500021B ZA 200500021 A ZA200500021 A ZA 200500021A ZA 200500021 A ZA200500021 A ZA 200500021A ZA 200500021 B ZA200500021 B ZA 200500021B
- Authority
- ZA
- South Africa
- Prior art keywords
- amine
- phenylsulfonyl
- compound
- formula
- ethyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims description 124
- 238000000034 method Methods 0.000 claims description 27
- -1 cycloheteroalkyl Chemical group 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 108091005435 5-HT6 receptors Proteins 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000019430 Motor disease Diseases 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 3
- JDACCOSLZDSTCR-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-4-methylindol-1-yl]-n,n-dimethylethanamine Chemical compound C12=C(C)C=CC=C2N(CCN(C)C)C=C1S(=O)(=O)C1=CC=CC=C1 JDACCOSLZDSTCR-UHFFFAOYSA-N 0.000 claims description 2
- UJKUGXNOEPNXDC-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-5-methoxyindol-1-yl]ethanamine Chemical compound C12=CC(OC)=CC=C2N(CCN)C=C1S(=O)(=O)C1=CC=CC=C1 UJKUGXNOEPNXDC-UHFFFAOYSA-N 0.000 claims description 2
- VRGUPYHXOLAFRJ-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-7-chloroindazol-1-yl]-n,n-dimethylethanamine Chemical compound C12=CC=CC(Cl)=C2N(CCN(C)C)N=C1S(=O)(=O)C1=CC=CC=C1 VRGUPYHXOLAFRJ-UHFFFAOYSA-N 0.000 claims description 2
- LLCSIVDCWGNQSS-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-(2-piperidin-1-ylethyl)indole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=CC=C11)=CN1CCN1CCCCC1 LLCSIVDCWGNQSS-UHFFFAOYSA-N 0.000 claims description 2
- HWVGSDITYJYUIT-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-(3-piperidin-1-ylpropyl)indazole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=CC=C11)=NN1CCCN1CCCCC1 HWVGSDITYJYUIT-UHFFFAOYSA-N 0.000 claims description 2
- WDUZWBLXLNNJQJ-UHFFFAOYSA-N 4-[3-[3-(benzenesulfonyl)-6-chloroindol-1-yl]propyl]morpholine Chemical compound C12=CC(Cl)=CC=C2C(S(=O)(=O)C=2C=CC=CC=2)=CN1CCCN1CCOCC1 WDUZWBLXLNNJQJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- GFDFZTFQPIBNSQ-UHFFFAOYSA-N (+)-homo-18-epiormosanine Natural products C1C(C23)CCCN3CN3CCCCC3C32CN2CCCCC2C1C3 GFDFZTFQPIBNSQ-UHFFFAOYSA-N 0.000 claims 3
- GFDFZTFQPIBNSQ-LDIYZUBKSA-N Homoormosanine Natural products N12[C@H]3[C@H](C[C@H]4[C@@H]5N(C[C@@]3([C@@H]3N(C1)CCCC3)C4)CCCC5)CCC2 GFDFZTFQPIBNSQ-LDIYZUBKSA-N 0.000 claims 3
- DJSNSCAIABQMNS-UHFFFAOYSA-N 2-(3-naphthalen-1-ylsulfonylindol-1-yl)ethanamine Chemical compound C1=CC=C2C(S(=O)(=O)C3=CN(C4=CC=CC=C43)CCN)=CC=CC2=C1 DJSNSCAIABQMNS-UHFFFAOYSA-N 0.000 claims 1
- ZMQOVOSHTIUYFU-UHFFFAOYSA-N 2-(3-thiophen-2-ylsulfonylindol-1-yl)ethanamine Chemical compound C12=CC=CC=C2N(CCN)C=C1S(=O)(=O)C1=CC=CS1 ZMQOVOSHTIUYFU-UHFFFAOYSA-N 0.000 claims 1
- YVISSGFCVCCZFH-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-2-methyl-3h-indazol-1-yl]-n,n-dimethylethanamine Chemical compound C12=CC=CC=C2N(CCN(C)C)N(C)C1S(=O)(=O)C1=CC=CC=C1 YVISSGFCVCCZFH-UHFFFAOYSA-N 0.000 claims 1
- BNOOQTLQHFYKBU-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-4-fluoroindazol-1-yl]-n,n-dimethylethanamine Chemical compound C12=C(F)C=CC=C2N(CCN(C)C)N=C1S(=O)(=O)C1=CC=CC=C1 BNOOQTLQHFYKBU-UHFFFAOYSA-N 0.000 claims 1
- LNMIDMDTFASVHY-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-6-chloroindazol-1-yl]ethanamine Chemical compound C12=CC=C(Cl)C=C2N(CCN)N=C1S(=O)(=O)C1=CC=CC=C1 LNMIDMDTFASVHY-UHFFFAOYSA-N 0.000 claims 1
- YFFMNVDYAYYDMQ-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-6-chloroindol-1-yl]ethanamine Chemical compound C12=CC=C(Cl)C=C2N(CCN)C=C1S(=O)(=O)C1=CC=CC=C1 YFFMNVDYAYYDMQ-UHFFFAOYSA-N 0.000 claims 1
- UJVHBPBCVGCFAM-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-(3-piperidin-1-ylpropyl)indole Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1=CC=CC=C11)=CN1CCCN1CCCCC1 UJVHBPBCVGCFAM-UHFFFAOYSA-N 0.000 claims 1
- NOELMURRATTYAK-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-[2-(dimethylamino)ethyl]indole-5-carbonitrile Chemical compound C12=CC(C#N)=CC=C2N(CCN(C)C)C=C1S(=O)(=O)C1=CC=CC=C1 NOELMURRATTYAK-UHFFFAOYSA-N 0.000 claims 1
- XTDCBEMTRJEXDB-UHFFFAOYSA-N 3-(benzenesulfonyl)-1-[2-(dimethylamino)ethyl]indole-7-carbonitrile Chemical compound C12=CC=CC(C#N)=C2N(CCN(C)C)C=C1S(=O)(=O)C1=CC=CC=C1 XTDCBEMTRJEXDB-UHFFFAOYSA-N 0.000 claims 1
- JUEUERKJONUNOL-UHFFFAOYSA-N 3-[3-(4-fluorophenyl)sulfonyl-5-methoxyindazol-1-yl]-n,n-dimethylpropan-1-amine Chemical compound C12=CC(OC)=CC=C2N(CCCN(C)C)N=C1S(=O)(=O)C1=CC=C(F)C=C1 JUEUERKJONUNOL-UHFFFAOYSA-N 0.000 claims 1
- NRPRZQXTJXIJQZ-UHFFFAOYSA-N 3-[3-(benzenesulfonyl)-5-methoxyindazol-1-yl]propan-1-amine Chemical compound C12=CC(OC)=CC=C2N(CCCN)N=C1S(=O)(=O)C1=CC=CC=C1 NRPRZQXTJXIJQZ-UHFFFAOYSA-N 0.000 claims 1
- LRLHHZCTHPBZSK-UHFFFAOYSA-N 4-[2-[3-(benzenesulfonyl)-6-chloroindazol-1-yl]ethyl]morpholine Chemical compound C12=CC(Cl)=CC=C2C(S(=O)(=O)C=2C=CC=CC=2)=NN1CCN1CCOCC1 LRLHHZCTHPBZSK-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000003595 spectral effect Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 7
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 208000015114 central nervous system disease Diseases 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- LYXFDNRZHVQSMF-UHFFFAOYSA-N 2-(benzenesulfonylmethyl)-4-methoxy-1-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(CS(=O)(=O)C=2C=CC=CC=2)=C1 LYXFDNRZHVQSMF-UHFFFAOYSA-N 0.000 description 2
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylamino-1-chloro-ethane hydrochloride Natural products CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 229940124801 5-HT6 antagonist Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 150000002473 indoazoles Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- JXTGICXCHWMCPM-UHFFFAOYSA-N (methylsulfinyl)benzene Chemical compound CS(=O)C1=CC=CC=C1 JXTGICXCHWMCPM-UHFFFAOYSA-N 0.000 description 1
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 1
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- LYFRUBQVZGVXPR-UHFFFAOYSA-N 1h-indole-3-thiol Chemical compound C1=CC=C2C(S)=CNC2=C1 LYFRUBQVZGVXPR-UHFFFAOYSA-N 0.000 description 1
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 1
- ZVPGRZHNTDZVKF-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)sulfonyl-5-methoxyindazol-1-yl]ethanamine Chemical compound C12=CC(OC)=CC=C2N(CCN)N=C1S(=O)(=O)C1=CC=C(F)C=C1 ZVPGRZHNTDZVKF-UHFFFAOYSA-N 0.000 description 1
- PUJFFBDCYXHTRY-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)sulfonyl-5-methoxyindol-1-yl]ethanamine Chemical compound C12=CC(OC)=CC=C2N(CCN)C=C1S(=O)(=O)C1=CC=C(F)C=C1 PUJFFBDCYXHTRY-UHFFFAOYSA-N 0.000 description 1
- YJQMSLMEYFKZAM-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-4-chloroindol-1-yl]-n,n-dimethylethanamine Chemical compound C12=C(Cl)C=CC=C2N(CCN(C)C)C=C1S(=O)(=O)C1=CC=CC=C1 YJQMSLMEYFKZAM-UHFFFAOYSA-N 0.000 description 1
- JELYKBZVZZNJBL-UHFFFAOYSA-N 2-[3-(benzenesulfonyl)-7-ethylindol-1-yl]-n,n-dimethylethanamine Chemical compound C=1N(CCN(C)C)C=2C(CC)=CC=CC=2C=1S(=O)(=O)C1=CC=CC=C1 JELYKBZVZZNJBL-UHFFFAOYSA-N 0.000 description 1
- XXFXFXQYKZSFER-UHFFFAOYSA-N 2-[3-[3-(benzenesulfonyl)indol-1-yl]propyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCN(C1=CC=CC=C11)C=C1S(=O)(=O)C1=CC=CC=C1 XXFXFXQYKZSFER-UHFFFAOYSA-N 0.000 description 1
- UYEXLMLQBNGMAW-UHFFFAOYSA-N 3-(benzenesulfonyl)-1h-indole Chemical compound C=1NC2=CC=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 UYEXLMLQBNGMAW-UHFFFAOYSA-N 0.000 description 1
- FAUCILQLCGXNLU-UHFFFAOYSA-N 3-(benzenesulfonyl)-2-methyl-1h-indole Chemical compound CC=1NC2=CC=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 FAUCILQLCGXNLU-UHFFFAOYSA-N 0.000 description 1
- JVNLPNNZJMCKLB-UHFFFAOYSA-N 3-(benzenesulfonyl)-2h-indazole Chemical compound N=1NC2=CC=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 JVNLPNNZJMCKLB-UHFFFAOYSA-N 0.000 description 1
- LZFIPKSWEDKWMX-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-methoxy-1-(2-pyrrolidin-1-ylethyl)indazole Chemical compound N1=C(S(=O)(=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1CCN1CCCC1 LZFIPKSWEDKWMX-UHFFFAOYSA-N 0.000 description 1
- MDYWRKZAPPZCKU-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-methoxy-1-(2-pyrrolidin-1-ylethyl)indole Chemical compound C1=C(S(=O)(=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1CCN1CCCC1 MDYWRKZAPPZCKU-UHFFFAOYSA-N 0.000 description 1
- VXQRAOAZAGDDJV-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-methoxy-1-(3-pyrrolidin-1-ylpropyl)indazole Chemical compound N1=C(S(=O)(=O)C=2C=CC=CC=2)C2=CC(OC)=CC=C2N1CCCN1CCCC1 VXQRAOAZAGDDJV-UHFFFAOYSA-N 0.000 description 1
- WSCJJWLCXUGWHX-UHFFFAOYSA-N 3-(benzenesulfonyl)-5-methoxy-1h-indole Chemical compound C12=CC(OC)=CC=C2NC=C1S(=O)(=O)C1=CC=CC=C1 WSCJJWLCXUGWHX-UHFFFAOYSA-N 0.000 description 1
- XIJAHRLASFMTGF-UHFFFAOYSA-N 3-benzylsulfanyl-1h-indole Chemical compound C=1NC2=CC=CC=C2C=1SCC1=CC=CC=C1 XIJAHRLASFMTGF-UHFFFAOYSA-N 0.000 description 1
- VLBFBZAPOLFEDT-UHFFFAOYSA-N 3-benzylsulfonyl-1h-indole Chemical compound C=1NC2=CC=CC=C2C=1S(=O)(=O)CC1=CC=CC=C1 VLBFBZAPOLFEDT-UHFFFAOYSA-N 0.000 description 1
- FQVDXLYJTMHMCG-UHFFFAOYSA-N 3-iodo-1h-indole Chemical compound C1=CC=C2C(I)=CNC2=C1 FQVDXLYJTMHMCG-UHFFFAOYSA-N 0.000 description 1
- DDJYYJIWIYUTRV-UHFFFAOYSA-N 3-sulfonylindazole Chemical class C1=CC=C2C(=S(=O)=O)N=NC2=C1 DDJYYJIWIYUTRV-UHFFFAOYSA-N 0.000 description 1
- BULFKQNIZODZDC-UHFFFAOYSA-N 3-sulfonylindole Chemical compound C1=CC=C2C(=S(=O)=O)C=NC2=C1 BULFKQNIZODZDC-UHFFFAOYSA-N 0.000 description 1
- AAHMJRYQBIJDFR-UHFFFAOYSA-N 4-[2-[3-(benzenesulfonyl)-6-chloroindol-1-yl]ethyl]morpholine Chemical compound C12=CC(Cl)=CC=C2C(S(=O)(=O)C=2C=CC=CC=2)=CN1CCN1CCOCC1 AAHMJRYQBIJDFR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JINOJFKHTZXTNH-UHFFFAOYSA-N [N].C1=CC=C2C=NNC2=C1 Chemical group [N].C1=CC=C2C=NNC2=C1 JINOJFKHTZXTNH-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38569502P | 2002-06-04 | 2002-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500021B true ZA200500021B (en) | 2006-06-28 |
Family
ID=29712202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200500021A ZA200500021B (en) | 2002-06-04 | 2005-01-03 | 1-(Aminoalkyl)-3-sylfonnylindole and -indazole derivatives as 5-hydroxytryptamine-5 ligands |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6727246B2 (fr) |
| EP (1) | EP1509501B1 (fr) |
| JP (1) | JP2005536473A (fr) |
| CN (1) | CN1656069A (fr) |
| AR (1) | AR040048A1 (fr) |
| AT (1) | ATE348806T1 (fr) |
| AU (1) | AU2003237355A1 (fr) |
| BR (1) | BR0311436A (fr) |
| CA (1) | CA2485871A1 (fr) |
| CR (1) | CR7566A (fr) |
| DE (1) | DE60310552T2 (fr) |
| DK (1) | DK1509501T3 (fr) |
| EC (1) | ECSP045473A (fr) |
| ES (1) | ES2279125T3 (fr) |
| MX (1) | MXPA04011315A (fr) |
| NO (1) | NO20044764L (fr) |
| NZ (1) | NZ536921A (fr) |
| RU (1) | RU2004139099A (fr) |
| TW (1) | TW200400177A (fr) |
| WO (1) | WO2003101962A1 (fr) |
| ZA (1) | ZA200500021B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL370342A1 (en) * | 2001-09-27 | 2005-05-16 | F.Hoffmann-La Roche Ag | Indole derivatives as cox ii inhibitors |
| JP2005518097A (ja) * | 2002-02-13 | 2005-06-16 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 集積半導体光学装置並びにこのような装置を製造する方法及び装置 |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| MXPA05008438A (es) * | 2003-02-14 | 2005-10-19 | Wyeth Corp | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. |
| EP1647549A1 (fr) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques |
| AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| WO2007002368A2 (fr) * | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Inhibiteurs non nucléosidiques de la transcriptase inverse |
| WO2007002481A2 (fr) * | 2005-06-28 | 2007-01-04 | Merck & Co., Inc. | Inhibiteurs non nucleosidiques de la transcriptase inverse |
| EP1898928A2 (fr) * | 2005-06-28 | 2008-03-19 | Merck & Co., Inc. | Inhibiteurs non nucléosidiques de la transcriptase inverse |
| MX2008002158A (es) * | 2005-08-15 | 2008-04-19 | Wyeth Corp | Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6. |
| JP5146766B2 (ja) * | 2005-08-15 | 2013-02-20 | ワイス・エルエルシー | ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体 |
| WO2007053353A2 (fr) * | 2005-10-28 | 2007-05-10 | Wyeth | Derives pyrrolo[2,3-f] et [3,2-f]isoquinolinone utilises en tant que ligands de la 5-hydroxytryptamine-6 |
| CN101432274A (zh) * | 2006-04-05 | 2009-05-13 | 惠氏公司 | 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物 |
| WO2007120596A1 (fr) * | 2006-04-12 | 2007-10-25 | Wyeth | DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6 |
| US20080318941A1 (en) * | 2007-05-24 | 2008-12-25 | Memory Pharmaceuticals Corporation | 4' substituted compounds having 5-ht6 receptor affinity |
| US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| KR20150032329A (ko) * | 2012-07-10 | 2015-03-25 | 에프. 호프만-라 로슈 아게 | 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 인다졸 |
| WO2018064094A1 (fr) | 2016-09-28 | 2018-04-05 | Bristol-Myers Squibb Company | Synthèse énantiosélective de composés de pyrroloindole |
| WO2018165501A1 (fr) * | 2017-03-10 | 2018-09-13 | Lycera Corporation | INDOLYLE SULFONAMIDE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGONISTES DE RORγ ET POUR LE TRAITEMENT DE MALADIES |
| CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654360A (en) | 1984-06-01 | 1987-03-31 | Syntex (U.S.A.) Inc. | 1,2,3-trisubstituted indoles for treatment of inflammation |
| FR2642755B1 (fr) | 1989-02-07 | 1993-11-05 | Sanofi | |
| US5132319A (en) | 1991-03-28 | 1992-07-21 | Merck Frosst Canada, Inc. | 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| EP1076657B1 (fr) | 1998-04-28 | 2004-08-04 | elbion AG | Nouveaux hydroxyindoles, leur utilisation comme inhibiteurs de la phosphodiesterase 4 et leur procede de preparation |
| GB9819032D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
| GB9820113D0 (en) | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| WO2001082909A2 (fr) | 2000-04-28 | 2001-11-08 | Baxter Healthcare Sa | Derives de 2-acyl-indole et leur utilisation comme agents antitumoraux |
| YU96103A (sh) * | 2001-06-07 | 2006-08-17 | F.Hoffmann-La Roche Ag. | Novi derivati indola sa afinitetom za 5-ht6 receptor |
-
2003
- 2003-05-19 TW TW092113450A patent/TW200400177A/zh unknown
- 2003-05-23 AR ARP030101812A patent/AR040048A1/es unknown
- 2003-06-03 WO PCT/US2003/017472 patent/WO2003101962A1/fr active IP Right Grant
- 2003-06-03 RU RU2004139099/04A patent/RU2004139099A/ru not_active Application Discontinuation
- 2003-06-03 AT AT03736818T patent/ATE348806T1/de not_active IP Right Cessation
- 2003-06-03 US US10/453,009 patent/US6727246B2/en not_active Expired - Fee Related
- 2003-06-03 AU AU2003237355A patent/AU2003237355A1/en not_active Withdrawn
- 2003-06-03 MX MXPA04011315A patent/MXPA04011315A/es active IP Right Grant
- 2003-06-03 DK DK03736818T patent/DK1509501T3/da active
- 2003-06-03 CN CNA038124998A patent/CN1656069A/zh active Pending
- 2003-06-03 CA CA002485871A patent/CA2485871A1/fr not_active Withdrawn
- 2003-06-03 ES ES03736818T patent/ES2279125T3/es not_active Expired - Lifetime
- 2003-06-03 JP JP2004509655A patent/JP2005536473A/ja active Pending
- 2003-06-03 BR BR0311436-8A patent/BR0311436A/pt not_active IP Right Cessation
- 2003-06-03 DE DE60310552T patent/DE60310552T2/de not_active Expired - Lifetime
- 2003-06-03 EP EP03736818A patent/EP1509501B1/fr not_active Expired - Lifetime
- 2003-06-03 NZ NZ536921A patent/NZ536921A/en unknown
-
2004
- 2004-11-03 NO NO20044764A patent/NO20044764L/no not_active Application Discontinuation
- 2004-11-04 CR CR7566A patent/CR7566A/es unknown
- 2004-12-02 EC EC2004005473A patent/ECSP045473A/es unknown
-
2005
- 2005-01-03 ZA ZA200500021A patent/ZA200500021B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ536921A (en) | 2006-06-30 |
| CA2485871A1 (fr) | 2003-12-11 |
| US20030232828A1 (en) | 2003-12-18 |
| AR040048A1 (es) | 2005-03-09 |
| CN1656069A (zh) | 2005-08-17 |
| CR7566A (es) | 2005-01-05 |
| EP1509501B1 (fr) | 2006-12-20 |
| WO2003101962A1 (fr) | 2003-12-11 |
| TW200400177A (en) | 2004-01-01 |
| DK1509501T3 (da) | 2007-03-12 |
| ATE348806T1 (de) | 2007-01-15 |
| RU2004139099A (ru) | 2005-06-10 |
| US6727246B2 (en) | 2004-04-27 |
| NO20044764L (no) | 2005-01-03 |
| AU2003237355A1 (en) | 2003-12-19 |
| JP2005536473A (ja) | 2005-12-02 |
| ES2279125T3 (es) | 2007-08-16 |
| DE60310552T2 (de) | 2007-09-27 |
| EP1509501A1 (fr) | 2005-03-02 |
| DE60310552D1 (de) | 2007-02-01 |
| BR0311436A (pt) | 2005-03-22 |
| ECSP045473A (es) | 2005-01-28 |
| MXPA04011315A (es) | 2005-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200500021B (en) | 1-(Aminoalkyl)-3-sylfonnylindole and -indazole derivatives as 5-hydroxytryptamine-5 ligands | |
| US7259165B2 (en) | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | |
| US7671079B2 (en) | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | |
| ZA200500022B (en) | 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligans | |
| US7608717B2 (en) | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | |
| US20050020575A1 (en) | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | |
| US20070099912A1 (en) | Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands | |
| US7534801B2 (en) | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | |
| KR20050024310A (ko) | 5-하이드록시트립타민-6-리간드로서의1-(아미노알킬)-3-설포닐인돌 및 -인다졸 유도체 |